Left ventricular hypertrophy detected by echocardiography in HIV-infected patients

European Journal of Internal Medicine

Volumn 24, Issue 6, 2013, Pages 558-561

  Pombo, Marta ^a   Olalla, Julián ^a   Del Arco, Alfonso ^a   De La Torre, Javier ^a   Urdiales, Daniel ^a   Aguilar, Ana ^a   Prada, José Luis ^a   García Alegría, Javier ^a   Ruiz Mateas, Francisco ^a  

^a Agencia Hospitalaria Costa Del Sol ^*  (Spain)

Author keywords

Echocardiography; HIV; Hypertrophy; Left ventricular

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; SMOKING; TRANSTHORACIC ECHOCARDIOGRAPHY; UNIVARIATE ANALYSIS;

ECHOCARDIOGRAPHY; HIV; HYPERTROPHY; LEFT VENTRICULAR;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CARBAMATES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG COMBINATIONS; DYSLIPIDEMIAS; ECHOCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LAMIVUDINE; LOPINAVIR; MALE; MIDDLE AGED; NEVIRAPINE; ORGANOPHOSPHATES; ORGANOPHOSPHONATES; RISK FACTORS; RITONAVIR; SMOKING; SPAIN; SULFONAMIDES; ZIDOVUDINE;

EID: 84883553050     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.04.007     Document Type: Article

References (36)

1. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860 (Pubitemid 28135961)
2. C. Smith, C.A. Sabin, J.D. Lundgren, R. Thiebaut, R. Weber, and M. Law Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study AIDS 24 2010 1537 1548
3. F. Islam, J. Wu, J. Jansson, and D. Wilson Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis HIV Med 13 2012 453 468
4. N. Friis-Moller, P. Reiss, C.A. Sabin, R. Weber, A. Monforte, and W. El-Sadr Class of antiretroviral drugs and the risk of myocardial infarction N Engl J Med 356 2007 1723 1735 (Pubitemid 46658704)
5. W.M. El-Sadr, J.D. Lundgren, J.D. Neaton, F. Gordin, D. Abrams, and R.C. Arduino CD4 + count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296 (Pubitemid 44837777)
6. M.G. van Vonderen, Y.M. Smulders, C.D. Stehouwer, S.A. Danner, C.M. Gundy, and F. Vos Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy J Acquir Immune Defic Syndr 50 2009 153 161
7. P.Y. Hsue, K. Ordovas, T. Lee, G. Reddy, M. Gotway, and A. Schnell Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium Am J Cardiol 109 2012 742 747
8. A.A. Butt, C.C. Chang, L. Kuller, M.B. Goetz, D. Leaf, and D. Rimland Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease Arch Intern Med 171 2011 737 743
9. A.I. Choi, E. Vittinghoff, S.G. Deeks, C.C. Weekley, Y. Li, and M.G. Shlipak Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons AIDS 25 2011 1289 1298
10. J. Olalla, D. Salas, A. Del Arco, J. De la Torre, J. Prada, and S. Machin-Hamalainen Ankle-branch index and HIV: the role of antiretrovirals HIV Med 10 2009 1 5
11. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566 (Pubitemid 20176696)
12. I. Kardys, J.W. Deckers, B.H. Stricker, W.B. Vletter, A. Hofman, and J.C. Witteman Echocardiographic parameters and all-cause mortality: the Rotterdam Study Int J Cardiol 133 2009 198 204
13. D.D. Savage, R.J. Garrison, W.B. Kannel, D. Levy, S.J. Anderson, and J. Stokes III The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study Circulation 75 1987 I26 I33
14. G. De Simone, V. Palmieri, J.N. Bella, A. Celentano, Y. Hong, and A. Oberman Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study J Hypertens 20 2002 323 331 (Pubitemid 34913799)
15. D.J. Lips, L.J. deWindt, D.J. van Kraaij, and P.A. Doevendans Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy Eur Heart J 24 2003 883 896 (Pubitemid 36559982)
16. R.B. Devereux, M.J. Roman, M. Paranicas, M.J. O'Grady, E.T. Lee, and T.K. Welty Impact of diabetes on cardiac structure and function: the strong heart study Circulation 101 2000 2271 2276 (Pubitemid 30317129)
17. A.M. Grandi, E. Nicolini, M. Giola, M. Gianni, A.M. Maresca, and C. Marchesi Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infection J Hum Hypertens 26 2012 570 576
18. P.Y. Hsue, P.W. Hunt, J.E. Ho, H.H. Farah, A. Schnell, and R. Hoh Impact of HIV infection on diastolic function and left ventricular mass Circ Heart Fail 3 2010 132 139
19. K.E. Mondy, J. Gottdiener, E.T. Overton, K. Henry, T. Bush, and L. Conley High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy Clin Infect Dis 52 2011 378 386
20. Q. Meng, J.A. Lima, H. Lai, D. Vlahov, D.D. Celentano, and S. Strathdee Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction J Acquir Immune Defic Syndr 30 2002 306 310 (Pubitemid 34774078)
21. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463 (Pubitemid 41821197)
22. N. Reinsch, P. Kahlert, S. Esser, A. Sundermeyer, K. Neuhaus, and N. Brockmeyer Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study Am J Cardiovasc Dis 1 2011 176 184
23. A. Mansoor, E.T. Golub, J. Dehovitz, K. Anastos, R.C. Kaplan, and J.M. Lazar The association of HIV infection with left ventricular mass/hypertrophy AIDS Res Hum Retroviruses 25 2009 475 481
24. K. Wachtell, J.N. Bella, P.R. Liebson, E. Gerdts, B. Dahlof, and T. Aalto Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study Hypertension 35 2000 6 12 (Pubitemid 30054229)
25. I. Schuster, G.J. Thoni, S. Ederhy, G. Walther, S. Nottin, and A. Vinet Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy Am J Cardiol 101 2008 1213 1217
26. Z.H. Tseng, E.A. Secemsky, D. Dowdy, E. Vittinghoff, B. Moyers, and J.K. Wong Sudden cardiac death in patients with human immunodeficiency virus infection J Am Coll Cardiol 59 2012 1891 1896
27. A.W. Haider, M.G. Larson, E.J. Benjamin, and D. Levy Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death J Am Coll Cardiol 32 1998 1454 1459 (Pubitemid 28522409)
28. K.C. Lund, and K.B. Wallace Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics Mitochondrion 4 2004 193 202 (Pubitemid 39549809)
29. S. De Wit, C.A. Sabin, R. Weber, S.W. Worm, P. Reiss, and C. Cazanave Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study Diabetes Care 31 2008 1224 1229
30. M. van der Valk, J.J. Kastelein, R.L. Murphy, F. van Leth, C. Katlama, and A. Horban Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile AIDS 15 2001 2407 2414 (Pubitemid 34014609)
31. R.B. Effros, C.V. Fletcher, K. Gebo, J.B. Halter, W.R. Hazzard, and F.M. Horne Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions Clin Infect Dis 47 2008 542 553
32. G.P. Schmid, B.G. Williams, J.M. Garcia-Calleja, C. Miller, E. Segar, and M. Southworth The unexplored story of HIV and ageing Bull World Health Organ 87 2009 162-162A
33. J.V. Lazarus, and K.K. Nielsen HIV and people over 50 years old in Europe HIV Med 11 2010 479 481
34. P.W. Hunt, J.N. Martin, E. Sinclair, B. Bredt, E. Hagos, and H. Lampiris T cell activation is associated with lower CD4 + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy J Infect Dis 187 2003 1534 1543 (Pubitemid 36578959)
35. J. Pieretti, M.J. Roman, R.B. Devereux, M.D. Lockshin, M.K. Crow, and S.A. Paget Systemic lupus erythematosus predicts increased left ventricular mass Circulation 116 2007 419 426 (Pubitemid 47196547)
36. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 2006 e442